Taking advantage of the HCP access rebound

The latest Veeva Pulse Field Trends Report is out and it discusses the change in access to HCPs. Even pre-pandemic, face-to-face meetings were in decline but the report highlights that this has bounced back, and some. The figure now sits at 60% across all specialities and it is clear that how interactions take place has changed.

Alongside in-person meetings, video interaction has grown. Interestingly there is also a correlation between video calls and an increase in face-to-face meetings. Data from the report shows a 2.5x increase in rep meetings with oncologists where a mixture of video calls and in-person meetings was used, as opposed to in-person alone.

It also highlights a disparity in access depending on which pharma company is trying to make contact – different specialities have different response rates to contact and communication differs across pharma significantly. The main takeaway from the report is that digitally-enabled reps have seen more success. It is, therefore, important to equip your reps with the right tools to make this process easier and ensure the HCP experience is relevant. And this includes enabling reps to share copyright scientific content in the form of ePrints directly with HCPs as part of their continuous dialogue. As recent research shows, HCPs are far more likely to change prescribing habits based on original journal content.

Tangent90 solutions support pharma companies to compliantly realise this distribution – in the rep channel as well as across all owned and third-party channels, for ePrints as well as related content  As a leading SaaS company, we work with 15 out of the top 25 global pharma companies. Our credentials are further evidenced by our Veeva Silver Certified Technology Partners status – one of the first-ever partners to achieve Silver status and of course the publishing industry partnerships. This well-established relationship enables us to deliver solutions that work in harmony with pharma’s existing ecosystem, allowing them to share digital copyright content directly with HCPs through pharma’s existing channels as well as third-party channels.

To find out more about how Tangent90 can support you to manage your scientific content distribution, please contact us at hello@tangent90.com.

Related news

First party data

The first-party data opportunity

The pharma industry has embraced the digital revolution and with that the opportunity to use more readily available data. However, effective digital engagement only works if first-party data (information a company collects directly from its customers and owns) is collected and subsequently used properly.

Marketing insight

Harnessing data-driven HCP engagement

Whether it’s via email, from a congress booth, or a website, we share content with our target audience constantly. For pharma, this content can be the difference between an HCP prescribing their drug or not. It is, therefore, important to understand what happens to that content after the initial interaction with the HCP.

Congress

Next-level engagement at congress

Around 40% of congresses are now operating a hybrid format therefore optimising the whole experience has become a priority, from the initial transaction to providing measurable outcomes – it requires a complete organisational approach.

Scroll to Top

Book A Demo

We use cookies to improve your experience on our website. By browsing this website, you agree to our use of cookies.